Evidence supporting the use of: Cannabidiol
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabidiol (CBD), a non-psychoactive compound found in cannabis, has garnered interest as a potential adjunct therapy for Parkinson’s Disease (PD). The scientific evidence supporting its use is limited but growing. Preclinical studies in animal models suggest that CBD may possess neuroprotective, anti-inflammatory, and antioxidant properties, which could theoretically benefit neurodegenerative diseases like PD. However, clinical evidence in humans remains sparse and mostly limited to small-scale studies and case reports.

A few small randomized controlled trials and open-label studies have investigated CBD’s effects on symptoms of PD, particularly non-motor symptoms such as psychosis, sleep disturbances, and quality of life. For instance, a 2014 study by Chagas et al. found that CBD improved quality of life in PD patients without psychiatric comorbidities, though motor symptoms were unchanged. Another small study found that CBD reduced psychotic symptoms in PD patients. However, these studies often suffer from small sample sizes and methodological limitations.

Major neurological and movement disorder societies currently do not recommend CBD as a standard treatment for PD due to insufficient high-quality evidence. While the compound appears to be well-tolerated, more robust, large-scale clinical trials are necessary to determine its efficacy and safety profile in this population.

In summary, while there is some scientific rationale and preliminary positive findings, evidence is limited and not yet strong enough to justify routine use of CBD in treating Parkinson’s Disease.

More about Cannabidiol
More about Parkinson's Disease

Products containing Cannabidiol

We currently have no products on Vitabase that contain this ingredient.